Table 2.

Clinical applications of M2BPGi in CHB patients

Category	Finding	M2BPGi level (C.O.I.) and point	Reference
Liver fibrosis	Significant fibrosis (≥F2) in CHB	≥1.06 C.O.I. (AUC, 0.753)	[73]
HCC occurrence/recurrence	Higher risk of HCC development in CHB patients	≥1.8 C.O.I. for patients without cirrhosis (P<0.001)	[78]
		≥1.8 C.O.I. for patients with cirrhosis (P=0.073)
	Low risk of HCC in HBeAg-negative patients	≤0.68 C.O.I. at baseline	[81]
	Risk for HCC development in CHB patients with cirrhosis treated with NAs	M2BPGi-based score* ≥652.5 at baseline	[83]
	Risk for HCC development in CHB patients treated with NAs	≥1.215 C.O.I. at 48 weeks	[84]
	HCC development in CHB patients	≥0.69 C.O.I. at baseline	[85]

M2BPGi, Mac-2 binding protein glycosylation isomer; CHB, chronic hepatitis B; C.O.I., cut-off index; AUC, area under the curve; HCC, hepatocellular carcinoma; HBeAg, hepatitis B envelope antigen; NAs, nucleos(t)ide analogues.

^*M2BPGi-based score, 8 × age (years) + 7 × baseline M2BPGi (COI) + 10 × body mass index (kg/m²). The score was calculable in 171 CHB patients with cirrhosis with a median of 652.5 (IQR, 581.3, 709.4) point.